Free Trial
NASDAQ:LIXT

Lixte Biotechnology 11/12/2024 Earnings Report

Lixte Biotechnology logo
$1.28 +0.02 (+1.91%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$1.32 +0.04 (+3.20%)
As of 04/25/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lixte Biotechnology EPS Results

Actual EPS
-$0.44
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lixte Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lixte Biotechnology Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Lixte Biotechnology's next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Lixte Biotechnology Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Lixte Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lixte Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lixte Biotechnology and other key companies, straight to your email.

About Lixte Biotechnology

Lixte Biotechnology (NASDAQ:LIXT), a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

View Lixte Biotechnology Profile

More Earnings Resources from MarketBeat